MIDATECH2016ANNUALGENERALMEETING11MAY2016

2

Disclaimer

Certain statements in this presentation may constitute “forward-looking statements” within the meaning of legislation in the United Kingdom and/or United States. Such forward-lookingstatements include, but are not limited to, statements regarding the expected completion of the acquisition, any expected free cash flow generation, any expected NASDAQ listing, anymarket and growth opportunities, the amount of anticipated cost synergies and other bene fits associated with the acquisition and other statements that are not historical fact. In somecases, you can identify forward-looking statements by the use of words such as “may,” “could,” “expect,” “intend, ” “plan,” “seek,” “anticipate,” “believe,” “potential,” “estimate,”“predict,” “potential,” or “continue” or the negative of these terms or other comparable terminology. You should not place undue reliance on forward-looking statements because theyinvolve known and unknown risks, uncertainties and other factors that are, in some cases, beyond our control and that could materially affect actual results, the acquisition, levels ofactivity, performance, or achievements.

Any forward-looking statements are based on currently available competitive, financial and economic data together with management’s views and assumptions regarding future eventsand business performance as of the time the statements are made and are subject to risks and uncertainties. We wish to caution you that there are some known and unknown factorsthat could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such forward-looking statements, including but notlimited to uncertainties as to how DARA stockholders may vote in respect to the merger proposal, the possibility that competing offers may be made, the possibility that various closingconditions for the Acquisition may not be satisfied or waived, operational challenges in achieving strategic objectives and executing plans, the risk that markets do not evolve asanticipated, the potential impact of the general economic conditions and competition in the industry. The risks included are not exhaustive.

Reference should be made to those documents that Midatech and DARA shall file from time to time or announcements that may be made by Midatech and/or DARA, in the case ofMidatech, in accordance with the London Stock Exchange AIM Rules for Companies (“AIM Rules”) and the Disclosure and Transparency Rules (“DTRs”) and in the case of DARA the USSecurities and Exchange Commissi on (“SEC”), including the section titled “Risk Factors” of DARA’s most recent Annual Report filed on Form 10-K and Quarterly Reports on Form 10-Q. Thisis in addition to the proxy statement/prospectus to be filed by Midatech and DARA, which shall contain and identify other important factors that could cause actual results to differmaterially from those contained in any projections or forward-looking statements. These forward-looking statements speak only as of the date of this announcement. All subsequentwritten and oral forward-looking statements by or concerning Midatech or DARA are expressly qualified in their entirety by the cautionary statements above. Except as may be requiredunder the AIM Rules or the DTRs or by relevant law in the UK or the US,Midatech and DARA do not undertake any obligation to publicly update or revise any forward-looking statementsbecause of new information, future events or otherwise arising.

3

ARapidlyGrowingInternationalSpecialtyPharmaceuticalCompany

Organisation

Technology

Organisation

CommercialForce

Technology

UK-basedpubliccompany(plc)• IPOonLondon’s AIM(MTPH)raising£32millionin2014• ADRslistedonNASDAQ(asMTP)inDec2015• c.100employeesacrossEurope&theUSA• Multipleacquisitionsdrivingfastrevenuegrowth• £16.2m/$24mcashasofDecember31st2015

Oncology/USCommercialTeam(40)• 6fast-growthmarketedproducts• Including1matureproduct inUS• Multipletopline growthexpected in2016vs2015

FullyintegratedR&Dcapabilitieswithtwoplatformtechnologies• FullR&Dcapability• Glycancoatedgoldnanoparticles• CAD“printed”sustainedreleaseparticles

4

PartnersUsingMidatech TechnologiesOncology/Neuroscience/Diabetes

CommercialOncology&SupportiveCare(US)

AcquisitionsLateStageStrategic&SynergisticAssets

Research&DevelopmentOrphanOncology /ImmunotherapyNeuro /Ophthalmology

OurApproach– BusinessModel

5

Midatech PharmaUS– marketedproducts

Comprehensiveofferingoforalsupportivecareproducts forcancerpatients

Buccal Tablet For Oral Candidiasis In AdultsSerious complication for patients undergoing radio/chemotherapy

Launched H2 2015 – first full year of sales 2016

Hyaluronic Acid Oral Gel For Oral Mucositis85-100% of H&N cancer patients on chemo/radiotherapy develop OM

Leads market in US strong growth expected 2016

Dual Iron DeliveryAnaemia treatment

Oral Spray Treatment For Dry Mouth Xerostomia

The only liquid oral tamoxifen available in the USBreast Cancer

ProductsthroughacquisitionofDARABioSciences Inc.(June2015)

• AddsNASDAQlistingandheadquartersinRaleigh,NCwith32USfieldorganisation

• MergerestablishesMidatechPharma’sUS-basedcommercialarm

• Productsfocusedononcologyandsupportivecare

• Portfolioofsixapprovedproducts

• Providesplatformforadditionalproductlicenseandacquisitionopportunities

Zuplenz®acquiredfromGalenaBiopharma (April2016)

Oralsolubletransmucosal filmtopreventpost-Operative,ChemotherapyandRadiation-InducedNausea andVomitinginUSLaunchedonApril11TH

Patentprotectedupto2029

2015HIGHLIGHTS

7

AcquiredDaraBiosciences,anoncologysupportivecarepharmaceuticalcompany• Addsanattractiveportfolioofcancersupportivecareproducts• EstablishesfullyintegratedUS-basedcommercialorganisation(Midatech PharmaUS)

2015Highlights

In2015Midatech executedagainstall keyareasofitsbusinessmodel

Establishedtworesearchcollaborationsthatexpandedpipeline• DanaFarbertotestMidatech’s targetednanomedicines againstglioblastoma• Ophthotech Corporationtoexploreopportunitiesinocularindications

AcquiredZuplenz (ondansetron),amarketedanti-emeticapprovedintheUS• Approvedforuseinmultipleindicationsandrecentlylaunchedintothe$10bnUSmarket• Bolstersmarketedoncologyproductportfolio

EstablishedsupplyagreementforQ-Octreotide signedwithCenturionPharma• FocusedondevelopmentandcommercialisationofproductsinTurkishmarket

CommencementofPhaseIIa studyofMidaform InsulinType1DiabetesProgram• SmalltrialtoestablishPK/PDprofileofMSL-001

8

Totalrevenuefortheyearup763%to£1.38m(2014:£0.16m,2013:£0.15m)

£16.18mcashanddepositsat31December2015(2014:£30.33m,2013:£2.39m)

Netlossaftertaxof£11.74m(2014:£8.82m,2013:£4.08m)

Netcashoutflowintheyearof£14.17m(2014:£27.94minflow, 2013:£2.25minflow)

Taxcreditreceivableof£1.20m(2014:£0.84m,2013:£0.80m)

2015FinancialHighlights

THERAPEUTICAREAS

10

Research Preclinical Phase I Phase II Market$

>$.64bn

>$2bn

>$.5bn

>$20bnMidaform® Insulin (JVMonoSol)MTD101JointVentureProduct

ImmunotherapyType1DiabetesVaccineMTX102

Cancer

OpsiSporinMTD202CNS/Ocular

Q-OctreotideMTD201

GlioblastomaMTR103

LiverHepatocellularCarcinoma MTR104

DevelopmentP ipel ine

SquamousCellCarcinoma MTR105

11

Targetcellsurfacereceptorsunique totumours

Maximise efficacy

Limitside effects&damagetohealthytissue

Focusonorphan liver(HCC) andbrain(GBM)cancer

BreakthroughGNPCancerTherapies:TargetingTumours

S e l e c t iv e T u mo urTa r g e t in g L iv e r & B r a in

12

Q-Octreo – MTD201

• Formulationcomplete• Increaseslikelihoodofbeingabletogettomarketfaster(2018vs2019)• Decisiontomanufactureinhousemade&willenableotherprojectsusingQ-Sphera

technology(eg Opthotech) tocapturemorevalue– Savestimec6monthsfromCMO– Costsaving

13

Intravitrealinjection intotheeyewithminimaltransfertotheblood

Uveitisgrowingrapidly~$1.3bnmarket,currenttreatedbyeyedrops,

immuno-supressivesorsystemicsteroids

13

Uveitis:OpsiSporin - Long-ActingDrugDelivery

OpsiSporin is3-monthlyinjectableformulationofcyclosporine fortreatmentofnon-infectiveuveitis

Recentpreclinicaldata:

ShowscleardoseresponseAllowsplanning forClinicalTrials

14

ExecutingonS trategicObjectivesto2019

Tohaveacquiredatleast2othervalueenhancingbusinessesQ-Chipin2014DARABioSciences– Dec2015Zuplenz(product)– Dec2015

Established andcontinue toexpandUScommercialpresence

EstablishEUcommercialorganisation

Tohave>2productslicensedtopartners•1todate

Tohave>1ownproductmarketed•Q-Octreo oncourse

Tobebreaking-even

Tobegrowingtop-linerevenueeachyearbyminimum50%•Estimatefor2015Vs2014=700%Growth•Marketexpectation2016Vs2015=700%Growth

Toberecognised asaleadingemergingspecialtypharmacompanyglobally

14

15

Summary

LeadingPlatformTechnologies• GNPTechnology• SustainedRelease

• UScommercialarmhas4productsinoncology,drivingfastrevenuegrowth

• Ownproductlaunchesfrom2018-19athighmargin

Midatech PharmaAnInternationalSpecialtyPharmaCompany

• Drivingrevenuegrowth• Developingclinicalportfolio• Seekingattractiveacquisitiontargets

On-trackExecutionOfThree-ProngedStrategyForGrowthAndValueCreation

Photographofsectionthroughneedleshowingmicrospheres

Representation ofagoldnanoparticle

15